CHAD
Chondroadherin
Also known as: CHAD_HUMAN, SLRR4A
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O15335
- Gene
- CHAD
- Ensembl
- ENSG00000136457
- Chromosome
- 17
- Canonical length
- 359 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to extracellular matrix
OverviewNCBI Gene
Chondroadherin is a cartilage matrix protein thought to mediate adhesion of isolated chondrocytes. The protein contains 11 leucine-rich repeats flanked by cysteine-rich regions. The chondroadherin messenger RNA is present in chondrocytes at all ages. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
359 residues, UniProt reviewed canonical sequence.
>O15335|CHAD
1 MVRPMLLLSL GLLAGLLPAL AACPQNCHCH SDLQHVICDK VGLQKIPKVS EKTKLLNLQR
61 NNFPVLAANS FRAMPNLVSL HLQHCQIREV AAGAFRGLKQ LIYLYLSHND IRVLRAGAFD
121 DLTELTYLYL DHNKVTELPR GLLSPLVNLF ILQLNNNKIR ELRAGAFQGA KDLRWLYLSE
181 NALSSLQPGA LDDVENLAKF HVDRNQLSSY PSAALSKLRV VEELKLSHNP LKSIPDNAFQ
241 SFGRYLETLW LDNTNLEKFS DGAFLGVTTL KHVHLENNRL NQLPSNFPFD SLETLALTNN
301 PWKCTCQLRG LRRWLEAKAS RPDATCASPA KFKGQHIRDT DAFRSCKFPT KRSKKAGRHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CHAD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 37 nTPM
Expression across tissuesHPA
Tissue
- liver: 37 nTPM
- cerebellum: 34 nTPM
- pancreas: 30 nTPM
- salivary gland: 23 nTPM
- cervix: 21 nTPM
- skeletal muscle: 15 nTPM
Single-cell type
- myonuclei: 16 nCPM
- papillary tip epithelial cells: 16 nCPM
- salivary duct cells: 15 nCPM
- oligodendrocyte progenitor cells: 15 nCPM
- goblet cells: 13 nCPM
- breast hormone-responsive cells: 9.8 nCPM
Immune cell
- memory B-cell: 22 nTPM
- naive B-cell: 8.1 nTPM
- total PBMC: 0.6 nTPM
- memory CD4 T-cell: 0.2 nTPM
- plasmacytoid DC: 0.2 nTPM
- myeloid DC: 0.1 nTPM
Brain region
- cerebellum: 31 nTPM
- basal ganglia: 11 nTPM
- hypothalamus: 7.8 nTPM
- amygdala: 7.4 nTPM
- cerebral cortex: 7.1 nTPM
- pons: 6.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.68
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CHAD as an antibody target. Whether an autoantibody or antibody against CHAD could matter depends on whether native CHAD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CHAD is annotated as secreted, so native CHAD circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CHAD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...